menu
    • menu

    Company profile for Mankind Pharma

    Mankind Mix GiF-PSE
    News
    Novartis Offers Payment Plan for High-Cost Heart Medicine

    27 May 2025

    // ECONOMICTIMES

    Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

    22 May 2025

    // INDPHARMAPOST

    Mankind Pharma`s Generics Proparacaine Receives Approval in US

    21 May 2025

    // FDA

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    BIO International Convention

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/8TC5EWpA250

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Related CompaniesRelated Companies

    About

    Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical company in 1995. Today, we have 11,000 employees and are heading towards a turnover of INR 50000 million. Our vast network includes 50 C&F agents and 7500+ stockists. We provide a wide range of products – Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular, Dermal, Erectile Dysfunction, and several other categories – across the nation.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mankind Pharmaindia-flag Flag
    Country
    Country
    India
    Address
    Address
    262, Okhla Industrial Estate, Phase-lll, New Delhi-110020
    Telephone
    Telephone
    +91 1146846700
    Client Email
    Email
    aparajita@mankindpharma.com
    Client Website
    Website
    https://www.mankindpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mankind-pharma-ltd/
    youtube
    YouTube
    http://www.youtube.com/@mankindpharma8266
    Twitter
    Twitter
    https://x.com/pharma_mankind
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Attending

    envelop Contact Supplier

    CPhI China

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-39644.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-64029.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-42058.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Products Under Development 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-44359.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-209.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024

    Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024

    The world of pharmaceuticals and biotechnology continued to evolve this year with strategic alliances reshaping industry contours. With mid-size deals taking centerstage, the growth trajectory appears to be marked by a balance of both caution and calculated ambition.The deal-making environment was robust in 2023, with over 2,000 unique pharma and biotech deals totaling more than US$ 410 billion, according to the PharmaCompass database. Last year, there were over 200 mergers and acquisitions (M&As) with transactions exceeding US$ 160 billion in total value. Oncology, infections and infectious diseases, and neurology had emerged as the top three therapeutic areas for deals.PharmaCompass’ analysis indicates that the momentum has been maintained in 2024. As of August 6, the industry had seen over 1,200 unique deals valued at more than US$ 230 billion, including over 120 M&A transactions surpassing US$ 60 billion in aggregate value. While oncology maintains its lead position, neurology and immunology have gained notable traction.The one big difference is that 2024 is yet to witness a mega-deal, comparable to Pfizer’s US$ 43 billion acquisition of Seagen in 2023 or Amgen’s US$ 27.8 billion Horizon buyout announced in 2022. The largest transaction thus far has been Novo Nordisk Foundation’s US$ 16.5 billion acquisition of Catalent, a contract development and manufacturing organization (CDMO).This compilation does not include deals related to acquisition of facilities, divestment, medical devices, diagnostics and animal health. We have considered deals announced, irrespective of when these transactions were completed. For a comprehensive overview of CDMO deals and developments in 2024, please refer to our dedicated roundup.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available) Vertex buys Alpine Immune for US$ 4.9 bn; Gilead’s CymaBay buyout pays off via FDA nodAmongst the biggest acquisitions of 2024 was Vertex Pharmaceuticals’ buyout of Alpine Immune Sciences for US$ 4.9 billion. It granted Vertex access to protein-based immunotherapies, including the promising povetacicept for IgA nephropathy, a serious kidney disease.Gilead Sciences’ acquisition of CymaBay Therapeutics for US$ 4.3 billion in February secured it access to seladelpar (Livdelzi), an experimental drug that received FDA’s accelerated approval this month for primary biliary cholangitis, a liver disease that affects the bile ducts. Eli Lilly bolstered its presence in the US$ 26.65 billion inflammatory bowel disease (IBD) market by purchasing Morphic Holding for approximately US$ 3.2 billion in July. Through this deal, Lilly gained the oral IBD therapy candidate MORF-057, which will offer a more convenient dosing option compared to injectable drugs currently available in the market. Lilly sees the IBD space as a way to diversify beyond obesity.Merck expanded its ophthalmology portfolio by acquiring Eyebiotech Limited for US$ 1.3 billion (plus US$ 1.7 billion in milestone payments), obtaining Restoret for diabetic macular edema and neovascular age-related macular degeneration.Japanese drugmaker Ono Pharmaceutical acquired Deciphera Pharmaceuticals for US$ 2.4 billion, gaining Qinlock for gastrointestinal stromal tumors and vimseltinib for tenosynovial giant cell tumors. Sanofi targeted rare diseases by purchasing Inhibrx for up to US$ 2.2 billion. The acquisition gave the French drugmaker access to INBRX-101 for Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver damage.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Novartis buys two oncology firms for their assets; J&J, Genmab join ADC bandwagonNovartis has been on a shopping spree, and has made two significant purchases this year. First, it acquired MorphoSys for € 2.7 billion (US$ 2.9 billion), thereby adding the promising bone-marrow cancer treatment pelabresib to its pipeline. Second, it announced the acquisition of Mariana Oncology for US$ 1 billion upfront (plus US$ 750 million in milestone payments), thereby expanding into radioligand therapies (RLTs) to treat cancers with high unmet need. RLTs take a targeted approach, delivering radiation to the tumor, while limiting damage to the surrounding cells.AstraZeneca entered the field of radioconjugates, which is a promising modality in the treatment of cancer, by acquiring Fusion Pharmaceuticals for US$ 2.4 billion.In January this year, Johnson & Johnson had announced the acquisition of antibody-drug-conjugate (ADC) developer Ambrx Biopharma for about US$ 2 billion. With this buyout, J&J has joined the likes of Bristol Myers Squibb, AbbVie and GSK who had entered this promising field through acquisitions last year.Similarly, Denmark’s Genmab bought ProfoundBio for US$ 1.8 billion in cash, boosting its oncology portfolio with three next-generation ADC candidates. This includes Rina-S, which recently received FDA’s fast track designation for the treatment of ovarian cancer.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Novartis signs multiple collaborations; GSK, Takeda, AbbVie sign billion-dollar dealsNovartis was not just busy signing M&A deals, it also signed a bevy of collaboration agreements. For instance, Shanghai-based Argo partnered Novartis on two early-stage RNA interference candidates for cardiovascular diseases, potentially earning the former up to US$ 4.2 billion plus tiered royalties.Novartis also agreed to pay up to US$ 3 billion (including US$ 150 million upfront) to Dren Bio to use the latter’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies to treat cancer.Moreover, the Swiss drugmaker expanded its peptide discovery collaboration with Japan-based PeptiDream in a deal worth over US$ 2.71 billion in milestone payments, plus an upfront payment of US$ 180 million. Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutic drugs after ADCs and Novartis is, thus far, the only big pharma with FDA-approved radioligand PDCs. GSK entered a groundbreaking partnership with Flagship Pioneering, potentially worth over US$ 7 billion, to identify and develop 10 novel drugs and vaccines. The deal, starting with respiratory and immunology drugs, involves US$ 720 million in upfront and milestone payments for each candidate. This collaboration leverages Flagship’s extensive portfolio of over 40 biopharma companies with drug development capabilities.There were two significant deals in the field of neuroscience. First, Takeda said it is paying Swiss biotech AC Immune US$ 100 million upfront with potential further payments of US$ 2.1 billion for an exclusive option to license global rights to an Alzheimer’s vaccine and related immunotherapies.Second, AbbVie and clinical stage biotech Gilgamesh Pharmaceuticals joined forces in a deal potentially worth over US$ 2 billion to develop a new class of psychedelic compounds for psychiatric conditions, combining AbbVie’s psychiatric expertise with Gilgamesh’s innovative neuroplastogen research platform.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Our viewDuring this year, companies like Novartis (with US$ 16.8 billion), GSK (US$ 14.5 billion), Sanofi (US$ 11.9 billion), Bristol Myers Squibb (US$ 11.6 billion), and AbbVie (US$ 9.1 billion) have made substantial investments in acquisitions, collaborations and other forms of dealmaking.Though the deal-making environment is robust, we notice a shift towards mid-size transactions. Alongside, we notice a growing interest in areas such as ADCs, radiopharmaceuticals, and protein-based immunotherapies, underscoring their growing importance in drug development. There has also been significant interest in silencing RNA (siRNA) therapeutics, highlighting the industry's focus on novel approaches to disease treatment. With the industry focusing on cutting-edge technologies that address unmet medical needs, we feel there is little reason to fret over the size of the deals.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3290

    https://www.pharmacompass.com/radio-compass-blog/novartis-gsk-sanofi-bms-shell-out-over-us-10-bn-in-dealmaking-as-mid-size-deals-take-centerstage-in-2024

    #PharmaFlow by PHARMACOMPASS
    22 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis Offers Payment Plan for High-Cost Heart Medicine
    Novartis Offers Payment Plan for High-Cost Heart Medicine

    27 May 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novartis-offers-payment-plan-for-high-cost-heart-medicine/articleshow/121421067.cms

    ECONOMICTIMES
    27 May 2025
    Share Share
    Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr
    Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

    22 May 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/mankind-pharma-posts-q4-fy25-consolidated-pat-rs-42511-cr-17186

    INDPHARMAPOST
    22 May 2025
    Share Share
    Mankind Pharma`s Generics Proparacaine Receives Approval in US
    Mankind Pharma`s Generics Proparacaine Receives Approval in US

    21 May 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219136

    FDA
    21 May 2025
    Share Share
    Mankind launches HealthOK's Veg Multivitamin Campaign
    Mankind launches HealthOK's Veg Multivitamin Campaign

    03 Apr 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/mankind-unveils-healthoks-100-vegetarian-multivitamin-tablets-campaign-with-archana-puran-singh-16968

    INDPHARMAPOST
    03 Apr 2025
    Share Share
    Mankind Launches Massive Health Mission At Mahakumbh
    Mankind Launches Massive Health Mission At Mahakumbh

    27 Jan 2025

    // PRESS FRELEASE

    https://www.mankindpharma.com/media/press-release/mankind-pharma-launches-45-day-healthcare-mission-at-mahakumbh-serving-thousands-of-pilgrims-with-free-health-check-ups

    PRESS FRELEASE
    27 Jan 2025
    Share Share
    Mankind Pharma slides after Q3 PAT slips 16% YoY to Rs 380 cr
    Mankind Pharma slides after Q3 PAT slips 16% YoY to Rs 380 cr

    24 Jan 2025

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/mankind-pharma-slides-after-q3-pat-slips-16-yoy-to-rs-380-cr-125012400521_1.html

    BUSINESS STD
    24 Jan 2025
    Share Share

    USDMF

    read-more
    read-more

    01

    Atorvastatin Calcium Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-01-12

    Pay. Date : 2021-11-29

    DMF Number : 34844

    Submission : 2020-06-05

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Atorvastatin Calcium Usp (process Ii...

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36365

    Submission : 2021-09-30

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Baclofen Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-06-21

    Pay. Date : 2022-06-01

    DMF Number : 37011

    Submission : 2022-04-27

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Cilnidipine

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39328

    Submission : 2024-05-01

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Clomipramine Hydrochloride Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-08-20

    Pay. Date : 2020-07-21

    DMF Number : 34935

    Submission : 2020-07-30

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Clozapine Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37540

    Submission : 2023-02-01

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Haloperidol Decanoate Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-03-30

    Pay. Date : 2020-02-20

    DMF Number : 34353

    Submission : 2020-02-26

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Haloperidol Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-01-21

    Pay. Date : 2019-11-14

    DMF Number : 34190

    Submission : 2019-11-22

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Midodrine Hydrochloride Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2025-01-16

    Pay. Date : 2025-01-06

    DMF Number : 40408

    Submission : 2024-11-18

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Nitrofurantoin Macrocrystals Usp

    India
    arrow
    BIO International Convention
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2019-04-26

    Pay. Date : 2019-03-05

    DMF Number : 33523

    Submission : 2019-02-23

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Mankind Pharma and get a quotation

    Mankind Pharma is a supplier offers 45 products (APIs, Excipients or Intermediates).

    Find a price of Atorvastatin bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Clomipramine Hydrochloride bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Haloperidol bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Haloperidol Decanoate bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Nitrofurantoin bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Pantoprazole Sodium bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Propranolol Hydrochloride bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Rosuvastatin Calcium bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Ticagrelor bulk with DMF, CEP offered by Mankind Pharma

    Find a price of Atorvastatin bulk with DMF offered by Mankind Pharma

    Find a price of Baclofen bulk with DMF offered by Mankind Pharma

    Find a price of Cilnidipine bulk with DMF offered by Mankind Pharma

    Find a price of Clozapine bulk with DMF offered by Mankind Pharma

    Find a price of Midodrine bulk with DMF offered by Mankind Pharma

    Find a price of Pantoprazole Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Ranolazine bulk with DMF offered by Mankind Pharma

    Find a price of Revefenacin bulk with DMF offered by Mankind Pharma

    Find a price of Rocuronium Bromide bulk with DMF offered by Mankind Pharma

    Find a price of Sacubitril Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Sacubitril-Valsartan bulk with DMF offered by Mankind Pharma

    Find a price of Sitagliptin Phosphate bulk with DMF offered by Mankind Pharma

    Find a price of Succinylcholine Chloride bulk with DMF offered by Mankind Pharma

    Find a price of Sugammadex Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Telmisartan bulk with DMF offered by Mankind Pharma

    Find a price of Valsartan bulk with DMF offered by Mankind Pharma

    Find a price of EMPAGLIFLOZIN (PROCESS II) bulk with DMF offered by Mankind Pharma

    Find a price of Brivaracetam bulk offered by Mankind Pharma

    Find a price of Dydrogesterone bulk offered by Mankind Pharma

    Find a price of Empagliflozin bulk offered by Mankind Pharma

    Find a price of Ensifentrine bulk offered by Mankind Pharma

    Find a price of Etoricoxib bulk offered by Mankind Pharma

    Find a price of Fezolinetant bulk offered by Mankind Pharma

    Find a price of Lasmiditan bulk offered by Mankind Pharma

    Find a price of Latanoprostene Bunod bulk offered by Mankind Pharma

    Find a price of Lifitegrast bulk offered by Mankind Pharma

    Find a price of Netarsudil bulk offered by Mankind Pharma

    Find a price of Netarsudil Mesylate bulk offered by Mankind Pharma

    Find a price of Obeticholic Acid bulk offered by Mankind Pharma

    Find a price of Perfluorohexyloctane bulk offered by Mankind Pharma

    Find a price of Resmetirom bulk offered by Mankind Pharma

    Find a price of Semaglutide bulk offered by Mankind Pharma

    Find a price of Suzetrigine bulk offered by Mankind Pharma

    Find a price of Upadacitinib bulk offered by Mankind Pharma

    Find a price of Ursodeoxycholic Acid bulk offered by Mankind Pharma

    Find a price of Xanomeline bulk offered by Mankind Pharma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search